153 related articles for article (PubMed ID: 37925171)
1. Multi-omics analysis reveals PUS1 triggered malignancy and correlated with immune infiltrates in NSCLC.
Tan Y; Wang Z; Wang Y; Tian X; Huang Y; Wu G; Lu J
Aging (Albany NY); 2023 Nov; 15(21):12136-12154. PubMed ID: 37925171
[TBL] [Abstract][Full Text] [Related]
2. PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma.
Li L; Zhu C; Xu S; Xu Q; Xu D; Gan S; Cui X; Tang C
Aging (Albany NY); 2023 Jun; 15(11):5215-5227. PubMed ID: 37315299
[TBL] [Abstract][Full Text] [Related]
3. Pseudouridine synthetase Pus1 of Saccharomyces cerevisiae: kinetic characterisation, tRNA structural requirement and real-time analysis of its complex with tRNA.
Arluison V; Buckle M; Grosjean H
J Mol Biol; 1999 Jun; 289(3):491-502. PubMed ID: 10356324
[TBL] [Abstract][Full Text] [Related]
4. RNA:pseudouridine synthetase Pus1 from Saccharomyces cerevisiae: oligomerization property and stoichiometry of the complex with yeast tRNA(Phe).
Arluison V; Batelier G; Riès-Kautt M; Grosjean H
Biochimie; 1999 Jul; 81(7):751-6. PubMed ID: 10492022
[TBL] [Abstract][Full Text] [Related]
5.
Lan C; Huang X; Liao X; Zhou X; Peng K; Wei Y; Han C; Peng T; Wang J; Zhu G
Pharmgenomics Pers Med; 2023; 16():337-355. PubMed ID: 37091827
[TBL] [Abstract][Full Text] [Related]
6. Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
Hu YX; Diao LT; Hou YR; Lv G; Tao S; Xu WY; Xie SJ; Ren YH; Xiao ZD
Hepatology; 2023 Nov; ():. PubMed ID: 38015993
[TBL] [Abstract][Full Text] [Related]
7. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
10. Systems biology strategy and experimental validation to uncover the pharmacological mechanism of Xihuang Pill in treating non-small cell lung cancer.
Zhuang Z; Huang D; Sheng ZR; Ye ZJ; Jiang H; Yuan Y; Qin B; Zhao Y; Pan HF; Tang Y
Phytomedicine; 2023 Jan; 108():154491. PubMed ID: 36368285
[TBL] [Abstract][Full Text] [Related]
11. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer.
Fang Z; Shen HY; Xu Q; Zhou HL; Li L; Yang SY; Zhu Z; Tang JH
Front Oncol; 2022; 12():1030571. PubMed ID: 36457503
[TBL] [Abstract][Full Text] [Related]
15. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
[TBL] [Abstract][Full Text] [Related]
16. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
17. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
[TBL] [Abstract][Full Text] [Related]
18. Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer.
Imai H; Onozato R; Kaira K; Kawashima S; Masubuchi K; Tajima K; Minato K
Oncology; 2022; 100(2):89-100. PubMed ID: 34844253
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
Li H; Wu C; Chang W; Zhong L; Gao W; Zeng M; Wen Z; Mai S; Chen Y
Front Biosci (Landmark Ed); 2023 Oct; 28(10):243. PubMed ID: 37919070
[TBL] [Abstract][Full Text] [Related]
20. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
